Kupffer cells dictate hepatic responses to the atherogenic dyslipidemic insult
Open Access
- 11 March 2024
- journal article
- research article
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 3 (3) , 356-371
Abstract
Apolipoprotein-B (APOB)-containing lipoproteins cause atherosclerosis. Whether the vasculature is the initially responding site or if atherogenic dyslipidemia affects other organs simultaneously is unknown. Here we show that the liver responds to a dyslipidemic insult based on inducible models of familial hypercholesterolemia and APOB tracing. An acute transition to atherogenic APOB lipoprotein levels resulted in uptake by Kupffer cells and rapid accumulation of triglycerides and cholesterol in the liver. Bulk and single-cell RNA sequencing revealed a Kupffer-cell-specific transcriptional program that was not activated by a high-fat diet alone or detected in standard liver function or pathological assays, even in the presence of fulminant atherosclerosis. Depletion of Kupffer cells altered the dynamic of plasma and liver lipid concentrations, indicating that these liver macrophages help restrain and buffer atherogenic lipoproteins while simultaneously secreting atherosclerosis-modulating factors into plasma. Our results place Kupffer cells as key sentinels in organizing systemic responses to lipoproteins at the initiation of atherosclerosis.Keywords
Funding Information
- Vetenskapsrådet (2020-01593, 2023-02014)
This publication has 50 references indexed in Scilit:
- Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage nichesCell, 2022
- Integrated analysis of multimodal single-cell dataCell, 2021
- Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK BiobankEBioMedicine, 2020
- Enzymatic Quantification of Liver Lipids After Folch Extraction2020
- Liver-Derived Signals Sequentially Reprogram Myeloid Enhancers to Initiate and Maintain Kupffer Cell IdentityImmunity, 2019
- Mouse models of nonalcoholic steatohepatitis in preclinical drug developmentDrug Discovery Today, 2017
- Applications and Limitations of Mouse Models for Understanding Human AtherosclerosisCell Metabolism, 2017
- Malondialdehyde epitopes are sterile mediators of hepatic inflammation in hypercholesterolemic miceHepatology, 2016
- A role for the apoptosis inhibitory factor AIM/Spα/Api6 in atherosclerosis developmentCell Metabolism, 2005
- Kupffer cell depletion by liposome-delivered drugs: Comparative activity of intracellular clodronate, propamidine, and ethylenediaminetetraacetic acidHepatology, 1996